quinoxalines has been researched along with glucagon-like peptide 1 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Flatt, PR; Green, BD; Irwin, N; Patterson, S | 1 |
| Bradley, SJ; Coopman, K; Huang, Y; Johnston, N; Wilkinson, GF; Willars, GB | 1 |
| Cheong, YH; Kaang, BK; Kim, MK; Son, MH | 1 |
| Li, N; Lu, J; Willars, GB | 1 |
| Edwards, IJ; Lilly, NA; Richards, JE; Trapp, S; Williams, DL; Yao, P | 1 |
| Huang, S; Leng, Y; Ma, S; Ning, M; Shen, J; Yang, W; Ye, Y; Zhang, L | 1 |
| Chen, Z; Guo, Y; Hou, Z; Li, F; Liu, H; Wang, N; Wang, Y; Xue, X; Zhou, Y | 1 |
7 other study(ies) available for quinoxalines and glucagon-like peptide 1
| Article | Year |
|---|---|
Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
Topics: Animals; Biomimetic Materials; Blood Glucose; Cell Line; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Mice; Molecular Weight; Peptides; Quinoxalines; Receptors, Glucagon; Sulfones; Venoms | 2010 |
Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor.
Topics: Biotransformation; Calcium; Cell Line; Cell Membrane; Cell Survival; Cyclic AMP; Data Interpretation, Statistical; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Green Fluorescent Proteins; GTP-Binding Proteins; Humans; Ligands; Peptide Fragments; Quinoxalines; Receptors, Glucagon; Signal Transduction; Sulfones; Trypan Blue | 2010 |
Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.
Topics: Animals; Calcium; CHO Cells; Cricetinae; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Peptides; Pyrimidines; Quinoxalines; Receptors, Glucagon; Sulfones; Venoms | 2012 |
Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.
Topics: Adenosine Monophosphate; Allosteric Regulation; Animals; Biotransformation; Calcium; Calcium Signaling; Cell Line; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Peptide Fragments; Peptides; Quinoxalines; Rats; Receptors, Glucagon; Sulfones; Transfection | 2012 |
GLP-1 action in the mouse bed nucleus of the stria terminalis.
Topics: Analysis of Variance; Animals; Dose-Response Relationship, Drug; Eating; Excitatory Amino Acid Antagonists; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Luminescent Proteins; Male; Membrane Potentials; Mice; Mice, Inbred C57BL; Mice, Transgenic; Patch-Clamp Techniques; Peptide Fragments; Proglucagon; Quinoxalines; Septal Nuclei; Stress, Psychological | 2018 |
TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice.
Topics: Animals; Cyclopropanes; Diabetes Mellitus, Experimental; Diet, High-Fat; Glucagon-Like Peptide 1; Glucose; HEK293 Cells; Homeostasis; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle Fibers, Skeletal; Muscle, Skeletal; Pyridines; Quinoxalines; Receptors, G-Protein-Coupled | 2019 |
A quinoxaline-based compound ameliorates bone loss in ovariectomized mice.
Topics: Animals; Bone Density; Bone Resorption; Disease Models, Animal; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Menopause; Mice; Mice, Inbred C57BL; Osteoclasts; Osteogenesis; Osteoporosis; Quinoxalines | 2021 |